S-1/A: Ontrak, Inc. Faces Critical Financial Hurdles Amidst New Public Offering and Nasdaq Delisting Risks

Sentiment:

Public Offering Prospectus 20 June 2025 4:52 PM

Ontrak, Inc. has filed an S-1/A registration statement for a public offering of common stock and warrants, seeking to raise capital while grappling with significant financial distress, a 'going concern' warning, and potential Nasdaq delisting.

Delay expectedOne of the largest active prospects paused its review of Ontrak's proposal while it continues to assess the company's financial stability and ability to deliver its program as a Medicaid provider, delaying the expected timeline to move to the final contracting phase.

Capital raiseThe document details a 'reasonable best efforts' public offering of up to 4,666,666 shares of common stock and up to 18,666,664 warrants.The offering includes pre-funded warrants for purchasers whose beneficial ownership would exceed 4.99% (or 9.99%) of outstanding common stock.The assumed combined public offering price is $1.50 per share and four warrants, with an estimated net proceeds of approximately $6.0 million.The company intends to use the net proceeds for working capital and other general corporate purposes.The company also details a potential Seventh Amendment to the Keep Well Agreement with Acuitas, committing Acuitas to purchase up to $8.7 million in additional Demand Notes and potentially Uncommitted Demand Notes, subject to certain conditions.

Worse than expectedThe company explicitly states 'substantial doubt about our ability to continue as a going concern' and indicates that even with the proceeds from this offering, it will need additional capital to fund operations through the 12-month period following the prospectus date.The company reported negative working capital of $3.1 million and an average monthly cash burn rate of $0.9 million for the three months ended March 31, 2025, indicating a deteriorating financial position.The loss of a single health plan customer accounted for 59% of the company's 2024 revenue, signaling a significant and immediate negative impact on future revenue.One of the largest active prospects paused its review of the company's proposal due to concerns about financial stability and Medicaid provider status, indicating a direct negative impact on future business development.

Summary

Ontrak, Inc. is conducting a 'reasonable best efforts' public offering of up to 4,666,666 shares of common stock and up to 18,666,664 warrants, with an assumed combined public offering price of $1.50 per share and four warrants.
The company expects to raise approximately $6.0 million in net proceeds from this offering, which it believes will fund operations only through the end of 2025.
As of March 31, 2025, Ontrak reported total cash of $4.1 million and negative working capital of $3.1 million, with an average monthly cash burn rate from operations of $0.9 million for the three months ended March 31, 2025.
The company has incurred significant losses since its inception in 2003, and its financial statements include an explanatory paragraph about 'substantial doubt concerning the Company's ability to continue as a going concern'.
A major health plan customer, which accounted for 59% of the company's $6.5 million revenue in 2024, notified Ontrak of its intent not to continue services after December 2024.
As of May 31, 2025, approximately $15.8 million, including accrued paid-in-kind interest, was outstanding under the Keep Well Agreement with Acuitas Capital LLC, with $13.0 million payable after September 1, 2026, or 30 days after Acuitas purchases all $5.0 million in Non-Convertible Demand Notes.
Existing warrants held by Acuitas and November 2023 Warrants had their exercise prices reduced to $1.553 (or lower for some) and the aggregate shares subject to them increased from 42,304,917 to 56,134,451 due to anti-dilution provisions triggered by recent agreements.
The company intends to enter into a Seventh Amendment to the Keep Well Agreement, committing Acuitas to purchase up to $8.7 million in additional Demand Notes, with further potential warrant adjustments and stockholder approval requirements.
Ontrak is subject to a Nasdaq discretionary panel monitor until October 7, 2025, and faces increased risk of delisting if it fails to maintain compliance with any listing requirement, including the stockholders' equity rule.
The former CEO and chairman, Terren S. Peizer, who indirectly controls Acuitas (the largest stockholder with ~97% beneficial ownership), was convicted of securities fraud and insider trading, raising potential public interest concerns for Nasdaq listing.

Sentiment

Score: 2

Explanation: The company is in a highly precarious financial state, evidenced by a 'going concern' warning, negative working capital, high cash burn, and significant customer loss. While attempting a capital raise, it's a 'best efforts' offering with no minimum, adding uncertainty. The substantial debt to a related party (Acuitas, controlled by a convicted former CEO) and ongoing Nasdaq delisting risks further compound the negative outlook, suggesting a high probability of significant investor loss.

Negatives

The company has incurred significant losses since its inception and continues to experience net losses and negative cash flow from operations.
There is 'substantial doubt about our ability to continue as a going concern' due to insufficient capital to fund operations beyond 2025, even with the proceeds from this offering.
The company had negative working capital of $3.1 million and only $4.1 million in cash as of March 31, 2025.
A significant health plan customer, representing 59% of 2024 revenue ($6.5 million), will not continue services after December 2024.
One of the largest active prospects has paused its review of Ontrak's proposal due to concerns about the company's financial stability and Medicaid provider status.
The company has a substantial debt burden of approximately $15.8 million outstanding under the Keep Well Agreement as of May 31, 2025, with significant portions becoming payable in 2026.
A default under the Keep Well Agreement would have a material adverse effect on the company's financial condition and could lead to insolvency or bankruptcy.
The company is subject to a Nasdaq discretionary panel monitor until October 7, 2025, significantly increasing the risk of delisting if any continued listing requirement is not met.
The conviction of the former CEO and controlling shareholder, Terren S. Peizer, for securities fraud and insider trading, poses a reputational risk and could lead to Nasdaq exercising its discretionary public interest authority to delist the common stock.
The anti-dilution provisions in existing and new warrants could lead to substantial dilution for stockholders if the exercise price is reduced, potentially making it harder to raise future capital.
The offering is on a 'best efforts' basis with no minimum amount, meaning the company may not raise sufficient capital to meet its needs.

Risks

The company may sell fewer than all securities offered in this 'best efforts' offering, resulting in significantly less net proceeds than anticipated.
There is no assurance that the common stock will continue to be listed on Nasdaq, and the company is subject to a discretionary panel monitor until October 7, 2025, which limits its ability to regain compliance with listing requirements.
New investors will experience immediate and substantial dilution in the net tangible book value per share of common stock purchased.
Future equity offerings or other equity issuances will likely cause further dilution to stockholders, and new investors may have superior rights.
There is no established public trading market for the pre-funded warrants or warrants, limiting their liquidity.
The warrants will not be exercisable unless and until stockholder approval is obtained, and if not obtained, they will have no value.
The price-based anti-dilution provisions in the warrants could harm trading in the common stock and make it difficult for the company to obtain additional financing.
Sales of a substantial number of common stock shares in the market following this offering may depress the market price.
Purchasers who enter into a securities purchase agreement may have superior rights and remedies compared to other purchasers.
Management has broad discretion in the use of net proceeds, which may not be applied effectively, and Acuitas may require proceeds to repay existing debt.
Holders of pre-funded warrants and warrants will have no rights as common stockholders until exercise.
The warrants and pre-funded warrants are speculative in nature, and there is no assurance that the common stock price will exceed the exercise price.
The company needs additional capital to continue operations and execute its business strategy, and there is no guarantee it will raise adequate funds on favorable terms or at all, raising substantial doubt about its ability to continue as a going concern.
A default under the Keep Well Agreement would have material adverse consequences, potentially leading to insolvency or bankruptcy.
Acuitas Group Holdings, LLC, as the largest stockholder, has substantial influence over corporate matters, and its interests may not align with other stockholders.
The company is subject to ongoing litigation and may face future litigation, which could result in substantial liabilities.
The market price of the company's common stock and preferred stock may be volatile and adversely impacted by future events.
Anti-takeover provisions in the company's corporate documents and Delaware law could discourage, delay, or prevent a change in control, potentially causing the stock price to decline.

Future Outlook

Ontrak, Inc. anticipates that the net proceeds from this offering, combined with existing cash, will be sufficient to fund operations only through the end of 2025, indicating a continued need for additional capital. The company is optimistic about moving five active prospects, representing up to 20,000 Wholehealth+ lives and 40,000 Engage lives, to final contracting phases by the end of 2025, and expects new health plan customers to expand solutions after achieving clinical and financial outcomes. However, one large prospect has paused its review due to concerns about the company's financial stability and Medicaid provider status, potentially delaying expected timelines.

Management Comments

Management believes the net proceeds from this offering, combined with existing cash, will be sufficient to fund operations through the end of 2025.
Management is confident in the proposals delivered to five active prospects in later sales stages and is optimistic about moving towards final decisions with them before the end of 2025.
Management notes that newest health plan customers have indicated an interest in expanding solutions to additional populations, once clinical and financial outcomes are achieved.

Industry Context

Ontrak operates in the value-based behavioral healthcare sector, leveraging technology and analytics to identify and engage individuals with unmet health needs, particularly those with behavioral health issues exacerbating chronic medical conditions. This aligns with broader industry trends towards integrated care and cost-saving solutions for healthcare payors. However, the company's significant customer loss, negative working capital, and 'going concern' warning suggest it is struggling to compete effectively or scale its solutions in a challenging market, potentially due to intense competition, difficulties in demonstrating value, or operational inefficiencies.

Comparison to Industry Standards

Ontrak's financial health, characterized by negative working capital ($3.1 million), a high cash burn rate ($0.9 million/month), and a 'going concern' warning, falls significantly below the financial stability typically expected of established companies in the healthcare technology or value-based care industry.
The loss of a single customer accounting for 59% of 2024 revenue ($6.5 million) indicates a high customer concentration risk, which is generally considered poor practice compared to industry standards that emphasize diversified revenue streams.
The need for continuous capital raises, coupled with complex anti-dilution provisions in existing and new warrants, suggests a reliance on dilutive financing that is not typical for financially robust industry peers, such as larger, more stable health tech companies like Teladoc Health (TDOC) or Livongo (now part of Teladoc), which have achieved greater scale and profitability.
The Nasdaq discretionary panel monitor and delisting risks, exacerbated by the former CEO's legal issues, indicate corporate governance and operational challenges that are not aligned with best practices for publicly traded companies, especially when compared to well-governed industry leaders.
While the company's focus on 'value-based behavioral healthcare' and 'proprietary Advanced Engagement System' aligns with innovative industry trends, its inability to secure sufficient funding or retain major contracts suggests a struggle to translate its unique approach into sustainable financial performance, unlike successful models that demonstrate clear ROI for payors and achieve broader market acceptance.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	Since August 2023, holders of Series A Preferred Stock have had the right to elect two directors to the board, though no directors have been elected by them as of the prospectus date.	2023-08-01	Potentially increases influence of Series A Preferred Stockholders on board composition, but currently no direct impact as no directors have been elected.
Nasdaq Listing Compliance	The company is subject to a discretionary panel monitor for one year from October 7, 2024, meaning any future non-compliance with listing requirements will lead to a delist determination without a plan of compliance or additional time.	2024-10-07	Significantly heightened risk of delisting, as the company loses the usual grace period and opportunity to submit a compliance plan for future deficiencies. This could severely impact liquidity and investor confidence.
Warrant Anti-Dilution Provisions	The warrants offered in this offering, as well as certain existing warrants, contain price-based anti-dilution provisions that reduce the exercise price and proportionally increase the number of shares issuable if the company issues securities at a lower price.	Ongoing	These provisions can lead to substantial dilution for existing shareholders and make it more challenging for the company to raise future capital without triggering further dilution, potentially harming stock price and investor interest.
Stockholder Approval for Warrants	The exercise of the warrants offered is subject to obtaining stockholder approval in accordance with Nasdaq rules.	Upon issuance of warrants	Introduces uncertainty regarding the exercisability and value of the warrants, as failure to obtain approval would render them valueless. Requires company resources to solicit proxies/consents.

Legal Proceedings

The company is involved in various securities class actions and purported stockholder derivative complaints.
The company has incurred legal costs related to an investigation by the SEC and Department of Justice of its former chief executive officer and chairman of its board of directors, Terren S. Peizer.
In June 2024, a federal jury convicted Terren S. Peizer of one count of securities fraud and two counts of insider trading.
On April 29, 2025, the Court found that Mr. Peizer's insider trading resulted in avoided losses of $12,711,324 and ordered him to forfeit that amount.
Mr. Peizer is set to be sentenced on June 23, 2025.
Neither the company nor any other current or former director or employee has been charged by the DOJ or sued by the SEC in relation to Mr. Peizer's case.

Related Party Transactions

The company has a Master Note Purchase Agreement (Keep Well Agreement) with Acuitas Capital LLC, an entity indirectly wholly owned and controlled by Terren S. Peizer, the company's former chief executive officer and chairman.
As of May 31, 2025, approximately $15.8 million, including accrued paid-in-kind interest, was outstanding under the Keep Well Agreement.
Acuitas has purchased $5.0 million in August Demand Notes and committed to purchase up to an additional $5.0 million in Demand Notes and $5.0 million in Non-Convertible Demand Notes under the May 2025 Agreement.
Acuitas has provided waivers for the company's non-compliance with recurring revenue and liquidity covenants through June 30, 2025, and for the going concern qualification in the December 31, 2024 financial statements, in satisfaction of the company's claim for restitution related to Mr. Peizer's legal matters.
The company intends to enter into a Seventh Amendment to the Keep Well Agreement with Acuitas, which would terminate the May 2025 Agreement and commit Acuitas to purchase up to $8.7 million in Committed Demand Notes, with potential for additional Uncommitted Demand Notes.
Acuitas Group Holdings, LLC beneficially owns approximately 97% of the company's common stock as of May 31, 2025, giving it substantial influence over corporate matters.

Stakeholder Impact

**Shareholders**: Face significant dilution from the current offering and potential future equity issuances due to anti-dilution provisions. Existing shareholders' equity value is at high risk due to the company's 'going concern' status, substantial debt, and potential Nasdaq delisting. Acuitas's controlling stake (97% beneficial ownership) means its interests may not align with other shareholders, potentially limiting their influence.
**Employees**: The company's precarious financial position and 'going concern' warning create job insecurity. The need for additional capital and potential reevaluation of operations could lead to workforce reductions or cessation of operations.
**Customers**: The loss of a major health plan customer (59% of 2024 revenue) indicates a significant disruption in service provision. Concerns from a large prospect about financial stability and Medicaid provider status could deter new customer acquisition, impacting the company's ability to deliver its programs.
**Creditors**: Acuitas, as the primary secured creditor under the Keep Well Agreement, holds a first priority lien on the company's assets. In case of default, Acuitas's claims would take precedence, potentially leaving other creditors with little to no recovery.
**Suppliers**: The company's negative working capital and cash burn rate could lead to delays or difficulties in paying suppliers, potentially impacting relationships and operational continuity.

Next Steps

The company will proceed with the public offering of common stock and warrants.
The company will seek stockholder approval for the exercise of the warrants in accordance with Nasdaq rules, either via written consent or by calling a special meeting within 60 days of the warrant issuance date.
If stockholder approval for warrants is not obtained within 60 days, the company will call additional special meetings semi-annually until approval is secured.
The company intends to enter into a Seventh Amendment to the Keep Well Agreement with Acuitas, which will involve new Demand Notes and potential adjustments to existing warrants.
The company will continue efforts to secure new contracts with active prospects, aiming for final decisions by the end of 2025.
The company will continue to monitor its compliance with Nasdaq listing requirements, particularly stockholders' equity, to avoid a delist determination letter.

Key Dates

Date	Description
2003-09-29	Ontrak, Inc. incorporated in the State of Delaware.
2022-04-15	Master Note Purchase Agreement (Keep Well Agreement) entered into with Acuitas Capital LLC.
2023-11-01	Date after which Acuitas, in its sole discretion, may require net proceeds from capital contributions or equity issuance to be applied to August Demand Notes.
2023-11-14	Date of issuance of pre-funded common stock purchase warrant to Humanitario Capital LLC and common stock purchase warrant to Humanitario Capital LLC.
2023-11-14	Date of issuance of pre-funded common stock purchase warrant and common stock purchase warrant in a public offering.
2023-11-09	Letter Agreement dated between Ontrak, Inc. and Acuitas Capital LLC.
2023-12-01	Month in which additional shares of common stock were issued and Conversion Warrant exercise price was reduced due to conversion price being less than public offering price.
2024-03-28	Sixth Amendment to Master Note Purchase Agreement dated.
2024-04-01	Month in which a convertible note in the principal amount of $1,500,000 was issued to Acuitas.
2024-05-01	Month in which a convertible note in the principal amount of $1,500,000 was issued to Acuitas.
2024-06-01	Month in which a convertible note in the principal amount of $1,500,000 was issued to Acuitas.
2024-06-01	Month in which a federal jury convicted Mr. Peizer of one count of securities fraud and two counts of insider trading.
2024-08-01	Month in which a convertible note in the principal amount of $1,500,000 was issued to Acuitas.
2024-08-13	Agreement dated between the Company and Acuitas Capital LLC.
2024-09-01	Month in which a convertible note in the principal amount of $1,000,000 was issued to Acuitas.
2024-09-23	Effective date of the 1-for-15 reverse stock split of common stock.
2024-10-01	Month in which a convertible note in the principal amount of $1,000,000 was issued to Acuitas.
2024-10-07	Date Nasdaq confirmed the company regained compliance with the Minimum Bid Price Rule and began a one-year discretionary panel monitor period.
2024-10-08	Date of Warrant Amendment.
2024-10-01	Month in which the company was notified by a health plan customer of its intent not to continue using services after December 2024.
2024-10-01	Month in which 142,711 shares of common stock were issued upon cashless exercise of a warrant.
2024-12-31	End of fiscal year for which consolidated financial statements were prepared, with an unqualified going concern opinion waiver from Acuitas.
2025-03-01	Month in which a convertible note in the principal amount of $1,500,000 was issued to Acuitas.
2025-03-31	Company's total cash, negative working capital, and legal claims submitted/paid as of this date.
2025-04-08	Agreement dated between Ontrak, Inc., Acuitas Capital LLC and Terren S. Peizer, including waivers for covenant non-compliance.
2025-04-29	Court found Mr. Peizer's insider trading resulted in avoided losses of $12,711,324 and ordered forfeiture.
2025-05-01	Month in which a convertible note in the principal amount of $500,000 was issued to Acuitas.
2025-05-09	Date a Demand Note for $0.5 million and a Demand Warrant for ~609,756 shares (exercise price $1.64) were issued to Acuitas.
2025-05-19	Agreement (May 2025 Agreement) entered into between Ontrak and Acuitas, committing Acuitas to purchase up to $5.0 million in Demand Notes and $5.0 million in Non-Convertible Demand Notes.
2025-05-27	Date a convertible note in the principal amount of $1,300,000 was issued to Acuitas.
2025-05-31	Approximately $15.8 million outstanding under the Keep Well Agreement as of this date.
2025-06-11	Closing price of common stock on Nasdaq was $1.50 per share.
2025-06-15	Number of active prospects and plan lives as of this date.
2025-06-20	Date of the S-1/A filing.
2025-06-23	Mr. Peizer is set to be sentenced on this date.
2025-10-07	End date of the Nasdaq discretionary panel monitor period.
2025-12-31	Expected period through which net proceeds from this offering will fund operations.
2026-05-14	Maturity date for a portion of the Keep Well Agreement balance.
2026-09-01	Earliest date Acuitas agrees not to demand payment for $13.0 million of Demand Notes.

Recommendation

strong sell

Keywords

Ontrak Inc., OTRK, SEC filing, S-1/A, Public Offering, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, Nasdaq Listing, Delisting Risk, Going Concern, Dilution, Keep Well Agreement, Acuitas Capital, Terren S. Peizer, Behavioral Healthcare, Value-Based Care, Financial Health, Debt, Cash Burn, Customer Loss, Anti-Dilution Provisions, Corporate Governance, Securities Fraud

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.